Table 1.
Subject Demographics and Baseline Characteristics by Renal Function Group
| Normal Renal Function (n = 16) | Moderate Renal Impairment (n = 16) | P for Difference | |
|---|---|---|---|
| Age, years | 55 (7) | 69 (9) | N/A |
| Sex (male), n (%) | 11 (68.8) | 11 (68.8) | N/A |
| White, n (%) | 16 (100) | 16 (100) | N/A |
| Weight, kg | 78 (10.8) | 80.5 (16.6) | N/A |
| BMI, kg/m2 | 26.23 (2.89) | 27.88 (4.64) | N/A |
| eGFR, mL/min/1.73 m2 | 100.5 (6.0) | 49.1 (7.7) | N/A |
| Apolipoprotein A‐I, mg/dL | 141 (19.0) | 143 (21.3) | 0.828 |
| Cholesterol efflux capacity, % efflux/4 hours | |||
| Total | 9.03 (1.75) | 11.50 (2.49) | 0.003 |
| ABCA1‐independent | 7.02 (1.29) | 7.85 (1.56) | 0.110 |
| ABCA1‐dependent | 2.01 (1.22) | 3.65 (1.68) | 0.004 |
| Pre‐β1‐HDL, g/L | 0.016 (0.003) | 0.023 (0.01) | 0.014 |
| Total cholesterol, mg/dL | 191 (36) | 188 (34) | 0.834 |
| HDL‐cholesterol, mg/dL | 52 (8) | 53 (12) | 0.731 |
| HDL‐unesterified cholesterol, mg/dL | 15 (3) | 15 (3) | 1.000 |
| HDL‐esterified cholesterol, mg/dL | 37 (6) | 38 (9) | 0.692 |
| Non‐HDL‐cholesterol, mg/dL | 140 (37) | 136 (31) | 0.743 |
| Apolipoprotein B, mg/dL | 91 (24) | 89 (18) | 0.780 |
| Triglycerides, mg/dL | 132 (57) | 141 (63) | 0.687 |
| C‐reactive protein, mg/L | 1.7 (3.5) | 2.3 (3.9) | 0.645 |
| Comorbidities, n (%) | |||
| Type 2 diabetes mellitus | 0 | 4 (25.0) | n.d. |
| Hyperlipidemia | 0 | 1 (6.3) | n.d. |
| Hypertension | 0 | 13 (81.3) | n.d. |
| Concomitant medications, n (%) | |||
| Statins | 0 | 5 (31.3) | n.d. |
| ACE inhibitors | 0 | 10 (62.5) | n.d. |
| Thiazides | 0 | 5 (31.3) | n.d. |
ACE, angiotensin‐converting enzyme; BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; N/A, not applicable; n.d., not determined.
Values are shown as mean (standard deviation) unless otherwise stated.